Integrating these findings with clinical data from TCGA (Fig 1D, Table 1), it was observed that patients with elevated SLC2A3 expression had a reduced overall survival rate and higher expression levels were noted in patients with advanced T and N stages, pathologic grade, clinical grade, and tumor grade. This evidence concerns the gene SLC2A3 and neoplasm.